According to new data presented by Novo Nordisk at the European Congress on Obesity, "Wegovy" (semaglutide 2.4 mg and 7.2 mg) provides weight loss across all menopause stages in women, reducing heart disease and migraine risk.
"Wegovy" showed an average weight loss of 22.6% in premenopausal women with obesity. Over 4 out of 10 women lost 25% or more of their body weight.
Weight loss was consistent across all menopause stages and accompanied by significant reduction in waist circumference. Compared to those on menopausal hormone therapy alone, women taking "Wegovy" had a 42-45% lower migraine risk and 25% lower depression risk after six months.
